The asterisk on the headline numbers
24.2% vs 20.9% is the comparison every headline runs, and it's a cross-trial comparison: different populations, different durations (48 vs 72 weeks), different phases (2 vs 3), and Phase 2 results routinely shrink in Phase 3. The honest statement: retatrutide's trajectory - especially the unplateaued curve at 48 weeks - suggests a higher ceiling, and proof requires either its Phase 3 readouts or a head-to-head trial.
The mechanism difference in one paragraph
Both drugs suppress appetite through incretin pathways. Retatrutide's added glucagon agonism appears to increase energy expenditure - burning more, not just eating less - which is the leading explanation for the steeper curve, and also plausibly connected to its distinctive signals (heart rate, skin dysesthesia) covered in the side-effects report.
The only decision that exists today
Until approval, “retatrutide vs tirzepatide” is not a patient choice - it's tirzepatide (or semaglutide) now versus waiting. Gray-market “retatrutide” is not a third option: it's an unverified substance with explicit FDA warnings. Track the timeline on the approval tracker; do the math, if a trial protocol requires it, on the calculator.
Frequently asked questions
Is retatrutide stronger than tirzepatide?
Trial numbers point that way - 24.2% mean weight loss at 48 weeks (Phase 2) vs tirzepatide's 20.9% at 72 weeks (SURMOUNT-1) - but these are different trials, populations, and durations. The definitive answer requires head-to-head data, which doesn't exist yet.
Can I get retatrutide instead of tirzepatide?
Not legally, outside a clinical trial. Tirzepatide is FDA-approved (Mounjaro, Zepbound) and prescribable today; retatrutide is investigational with no legal route, and the FDA has warned about products sold online.
Will retatrutide replace tirzepatide?
Both are Eli Lilly drugs, so this is portfolio sequencing, not a rivalry. If Phase 3 confirms Phase 2, retatrutide likely launches as the higher-efficacy option while tirzepatide remains the established, insurable choice for years.
Sources: Jastreboff et al. NEJM (retatrutide Phase 2); SURMOUNT-1 NEJM (tirzepatide); FDA approval records and drug-alert statements.